Buchumschlag

21 | PROGNOSTIC VALUE OF CIRCULATING TUMOR DNA IN PATIENTS WITH ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA TREATED ON SWOG S1826

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	J. Paczkowska, M. Kaszkowiak, M. LeBlanc, C. Stewart, A. F. Herrera, J. C. Fernando del Castillo, S. M. Castellino, S. C. Rutherford, A. M. Evens, K. Davison, H. Li, D. Neuberg, M. Murakami, J. Makker, B. Kahl, J. P. Leonard, N. L. Bartlett, S. M. Smith, J. Y. Song, K. M. Kelly, G. Getz, J. W. Friedberg, M. A. Shipp
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Hematological Oncology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

418 | CIRCULATING TUMOR DNA ASSESSMENT IN PATIENTS WITH EARLY‐STAGE CLASSICAL HODGKIN LYMPHOMA TREATED WITH COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB
von: R. C. Lynch, et al.
Veröffentlicht: (2025)

22 | PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV) AND TUMOR SPREAD (Dmax) IN ADVANCED HODGKIN LYMPHOMA: ANCILLARY STUDY OF THE AHL2011 TRIAL
von: S. Kanoun, et al.
Veröffentlicht: (2025)

126 | THE EARLY‐STAGE CLASSIC HODGKIN LYMPHOMA INTERNATIONAL PROGNOSTICATION INDEX (E‐HIPI): AN INDIVIDUALIZED PREDICTION MODEL UTILIZING OBJECTIVE AND CONTINUOUS VARIABLES
von: A. M. Evens, et al.
Veröffentlicht: (2025)

729 | EXPERIENCE WITH VECADD IN ADVANCED CLASSIC HODGKIN LYMPHOMA IN PREGNANT AND NON‐PREGNANT FEMALE PATIENTS
von: A. S. Robertz, et al.
Veröffentlicht: (2025)

151 | CLINICAL VALIDITY OF NONINVASIVE GENOTYPING OF MCL AT DIAGNOSIS FROM BLOOD PLASMA BY CIRCULATING TUMOR DNA PROFILING
von: B. Tessoulin, et al.
Veröffentlicht: (2025)

727 | DO PATIENTS WITH CLASSIC HODGKIN LYMPHOMA TREATED WITH ABVD IN LOW‐MIDDLE INCOME COUNTRIES HAVE A HIGHER RISK OF NEUTROPENIA/FEBRILE NEUTROPENIA WITHOUT G‐CSF SUPPORT?
von: B. F. C. Galvão, et al.
Veröffentlicht: (2025)

561 | PROGNOSTIC IMPACT OF THE MUTATIONAL PROFILE IN FOLLICULAR LYMPHOMA TREATED WITH FIRST‐LINE IMMUNOCHEMOTHERAPY
von: J. Marco Ayala, et al.
Veröffentlicht: (2025)

12 | IMAGING BIOMARKERS FOR THE DEFINITION OF RESPONSE IN THE GHSG HD18, GHSG HD21 AND LYSA AHL2011 TRIALS FOR ADVANCED‐STAGE HODGKIN LYMPHOMA
von: J. Ferdinandus, et al.
Veröffentlicht: (2025)

37 | PATTERNS OF FATIGUE IN HIGH‐RISK PEDIATRIC HODGKIN LYMPHOMA (HL) TREATED WITH PEDIATRIC HODGKIN CONSORTIUM (PHC) BRENTUXIMAB VEDOTIN‐CONTAINING EUROPEAN‐DERIVED REGIMENS
von: A. M. Feraco, et al.
Veröffentlicht: (2025)

415 | CIRCULATING TUMOR DNA AT SCREENING AS A PROGNOSTIC MARKER IN UNTREATED FOLLICULAR LYMPHOMA FROM THE GALLIUM TRAIL USING A NEXT GENERATION SEQUENCING ASSAY
von: C. Lutterbeck, et al.
Veröffentlicht: (2025)

275 | RADIOTHERAPY IN PATIENTS WITH ADVANCED STAGE MANTLE CELL LYMPHOMA ACHIEVES DURABLE LOCAL TUMOR CONTROL—A SAKK/GLA/EMCL REAL‐WORLD‐ANALYSIS FROM THE EMCL‐REGISTRY
von: L. Simon, et al.
Veröffentlicht: (2025)

853 | CTEP TRIAL 10590, NORM: NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA PATIENTS TREATED IN A RANDOMIZED PHASE II TRIAL WITH EITHER RITUXIMAB OR MOSUNETUZUMAB
von: R. Steiner, et al.
Veröffentlicht: (2025)

133 | LONG‐TERM SURVIVAL TRENDS IN ADVANCED‐STAGE MANTLE CELL LYMPHOMA: A POOLED ANALYSIS OF SIX RANDOMIZED PHASE III TRIALS FROM 1996 TO 2020
von: L. Jiang, et al.
Veröffentlicht: (2025)

419 | MULTICENTER REAL‐WORLD OUTCOMES IN DIFFUSE LARGE B‐CELL LYMPHOMA PROFILED WITH A COMMERCIALLY‐AVAILABLE CIRCULATING TUMOR DNA ASSAY
von: P. Gould, et al.
Veröffentlicht: (2025)

373 | PROGNOSTIC VALUE OF 18F‐FDG PET/CT VOLUMETRIC PARAMETERS IN CHILDHOOD, ADOLESCENT, AND YOUNG ADULT HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW FROM THE SEARCH GROUP
von: C. Gowdy, et al.
Veröffentlicht: (2025)

850 | GOLSEEK‐2: A PHASE 2 RANDOMIZED, OPEN‐LABEL STUDY OF GOLCADOMIDE IN COMBINATION WITH RITUXIMAB IN PARTICIPANTS WITH NEWLY DIAGNOSED ADVANCED‐STAGE FOLLICULAR LYMPHOMA
von: P. Luigi Zinzani, et al.
Veröffentlicht: (2025)

A Coastal and Ocean Information Network for Caribbean marine resource management
von: Butler, M.J.A., et al.
Veröffentlicht: (1992)

A Habitat Mapping Program: the basis for a Caribbean Coastal Zone Information System
von: Butler, M.J.A., et al.
Veröffentlicht: (1999)

854 | SEQUENCING‐GUIDED CHEMOTHERAPY OPTIMIZATION USING REAL‐TIME EVALUATION IN NEWLY DIAGNOSED DLBCL WITH CIRCULATING TUMOR DNA: SHORTEN‐ctDNA
von: H. J. Cherng, et al.
Veröffentlicht: (2025)

849 | INTERIM PET‐ADAPTED DE‐ESCALATION CHEMOTHERAPY REGIMEN FOR ADVANCED STAGE cHL USING BRENTUXIMAB VEDOTIN, PEMBROLIZUMAB, DOXORUBICIN, AND DACARBAZINE
von: H. J. Lee, et al.
Veröffentlicht: (2025)

513 | PROGNOSTIC PREDICTIVE VALUE OF BASELINE 18F‐FDG PET/CT METABOLIC PARAMETERS IN HODGKIN’S LYMPHOMA
von: H. Zhang, et al.
Veröffentlicht: (2025)

153 | HARNESSING SYSTEMIC INFLAMMATION WITH CIRCULATING TUMOR DNA IMPROVES SURVIVAL PREDICTION IN LARGE B‐CELL LYMPHOMA
von: S. Leppä, et al.
Veröffentlicht: (2025)

374 | IMAGING PITFALLS IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT HODGKIN LYMPHOMA: A SEARCH FOR CAYAHL INITIATIVE TO BRIDGE MULTIDISCIPLINARY PATIENT CARE
von: N. Dakhallah, et al.
Veröffentlicht: (2025)

364 | THE ROLE OF STEM CELL TRANSPLANTATION IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE
von: E. Lucchini, et al.
Veröffentlicht: (2025)

231 | IMPACT OF RITUXIMAB EARLY ADMINISTRATION ON OUTCOMES IN ADVANCED STAGE LOW TUMOR BURDEN FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF PHASE III JCOG1411/FLORA STUDY
von: D. Maruyama, et al.
Veröffentlicht: (2025)

520 | THE ROLE OF LABORATORY PROGNOSTIC INDEX AND METABOLIC TUMOR VOLUME IN PREDICTING DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS POTENTIALLY CURABLE WITH R‐CHOP
von: S. Browne Arthur, et al.
Veröffentlicht: (2025)

524 | PROFILING OF CIRCULATING EPIGENETIC MARKS IN LYMPHOMA PATIENTS
von: K. Sienkiewicz, et al.
Veröffentlicht: (2025)

66 | MECHANISMS OF RESISTANCE TO CHECKPOINT INHIBITORS
von: M. Shipp
Veröffentlicht: (2025)

759 | UPDATED OUTCOMES OF P‐GEMD IN TREATMENT‐NAÏVE EARLY‐STAGE NON‐UPPER AERO‐DIGESTIVE TRACT OR ADVANCED‐STAGE EXTRANODAL NK/T CELL LYMPHOMA
von: J. Liang, et al.
Veröffentlicht: (2025)

732 | EXTENDED BRENTUXIMAB VEDOTIN LEAD‐IN AND ABBREVIATED AVD IN OLDER PATIENTS (> 60 YEARS) WITH ADVANCED HODGKIN LYMPHOMA AND HIGH COMORBIDITY (ECOG ≥ 2 AND/OR CIRS‐G > 10)
von: M. Bonanni, et al.
Veröffentlicht: (2025)

460 | CIRCULATING CAR T‐CELLS AFTER TREATMENT WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH R/R AGGRESSIVE B‐CELL LYMPHOMAS AND ITS ASSOCIATION TO TREATMENT OUTCOME
von: L. Olsson Werne, et al.
Veröffentlicht: (2025)

679 | FREQUENCY OF CD30 EXPRESSION AND PROGNOSTIC IMPACT IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA
von: M. Bellesso, et al.
Veröffentlicht: (2025)

477 | LONGITUDINAL MULTI‐OMICS INVESTIGATION IN IBRUTINIB‐BORTEZOMIB‐R‐CHOP‐TREATED DLBCL PATIENTS
von: S. Denker, et al.
Veröffentlicht: (2025)

Car-STAGE: Automated framework for large-scale high-dimensional simulated time-series data generation based on user-defined criteria
von: Almutairi, Asma A., et al.
Veröffentlicht: (2025)

Nutrigenomics and public Health
von: Getz, J., Adhikari K. & D. M. Medeiros
Veröffentlicht: (2010)

722 | HODGKIN LYMPHOMA: ARE WE LEAVING PATIENTS IN “CHECK”?
von: I. O. Ramos, et al.
Veröffentlicht: (2025)

487 | MicroRNAs TARGET TUMOR SUPPRESSOR GRK2 IN MALT1‐DEPENDENT DIFFUSE LARGE B‐CELL LYMPHOMA
von: J. Cheng, et al.
Veröffentlicht: (2025)

296 | LIMITED STAGE DIFFUSE LARGE B CELL LYMPHOMA IN THE MODERN ERA: REAL‐WORLD OUTCOMES IN AN INTERNATIONAL STUDY OF OVER ONE THOUSAND PATIENTS
von: Z. Loh, et al.
Veröffentlicht: (2025)

863 | RADIOTHERAPY IN PREGNANT PATIENTS WITH HODGKIN’S LYMPHOMA: CLINICAL OUTCOMES AND DOSIMETRIC ASSESSMENT
von: E. Wojciechowska‐Lampka, et al.
Veröffentlicht: (2025)

417 | TMTV < THAN 32.5 mL IMPAIRS THE SUCCESSFUL DETECTION OF ctDNA IN EARLY‐STAGE HODGIN LYMPHOMA PATIENTS—THE PRELIMINARY REPORT FROM THE RAFTING TRIAL
von: M. M. Bednarek, et al.
Veröffentlicht: (2025)